Erasca, INC

Erasca, Inc. announced the pricing of an upsized public offering of approximately $550 million of its common stock, with net proceeds expected to be around $516 million.

Erasca, Inc. announced updated preliminary Phase 1 data for its ERAS-0015 molecular glue, showing encouraging monotherapy responses and promising combination potential, alongside accelerated development plans.

Erasca, Inc. announced its first quarter 2026 financial results and provided business updates, highlighting progress in its RAS-targeting oncology pipeline and a strong cash position.

Erasca announced positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue, ERAS-0015, in patients with RAS-mutant solid tumors.

Erasca, Inc. announced a conference call to discuss preliminary Phase 1 data for ERAS-0015, but also disclosed a patent infringement and trade secret misappropriation letter from Revolution Medicines, Inc.

Erasca, Inc. has updated its guidance for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015, now expected no later than mid-May 2026.

Erasca, Inc. reported its first quarter 2026 financial results, highlighted by a significant in-process R&D expense related to a license expansion, while also disclosing a new intellectual property dispute with Revolution Medicines.

Erasca, Inc. reports reduced net losses and extended cash runway into the second half of 2028, driven by strategic reprioritization and pipeline advancements.

Erasca, Inc. reported reduced net losses and extended its cash runway into the second half of 2028, while strategically reprioritizing its oncology pipeline.

Erasca, a clinical-stage oncology company, announces its Q1 2025 financial results and a strategic shift to prioritize its RAS-targeting programs.

Erasca Inc. reported its third quarter 2024 financial results, highlighting a strategic reprioritization and advancements in its clinical programs.

Erasca Inc. announced its second quarter 2024 financial results, highlighting a strategic shift to focus on its naporafenib program and two new RAS-targeting programs.

Erasca, a clinical-stage oncology company, announces its full year 2024 results, highlighting progress in its RAS/MAPK pathway-focused pipeline and a strategic reprioritization of resources.

Erasca's 2023 10-K filing highlights its focus on developing therapies for RAS/MAPK pathway-driven cancers, with three clinical-stage programs and a deep pipeline.

Valerie Denise Harding, a Director at Erasca, Inc., acquired stock options for 29,888 shares of common stock on June 26, 2026.

Erasca, Inc. director Jean I. Liu acquired 29,888 stock options with an exercise price of $16.01, vesting on June 26, 2027.

Erasca, Inc. director Pratik S. Multani acquired 29,888 stock options with an exercise price of $16.01, vesting on June 26, 2027.

Director Alexander W. Casdin of Erasca, Inc. acquired 29,888 stock options on June 26, 2026, as detailed in a Form 4 filing.

Director Julie Hambleton acquired 29,888 stock options in Erasca, Inc. on June 26, 2026, with an exercise price of $16.01.

Director James Arthur Bristol acquired 29,888 stock options in Erasca Inc. (ERAS) on June 26, 2026, with vesting contingent on continued service.

Erasca, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026, to elect directors and ratify auditors.

Erasca, Inc. will hold its annual stockholders meeting on June 24, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Erasca, Inc. announces its annual stockholders meeting to be held virtually on June 24, 2025, featuring proposals for director elections and ratification of the independent accounting firm.

Erasca, Inc. will hold its annual stockholders meeting on June 20, 2024, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Erasca, Inc. announces its annual stockholders meeting to be held virtually on June 20, 2024, to elect directors and ratify the appointment of its independent accounting firm.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 16,157,175 shares, representing 5.2% of Erasca, Inc.'s common stock as of March 31, 2026.

Suvretta Capital Management and Aaron Cowen have filed an amendment to their Schedule 13G regarding their holdings in Erasca, Inc.

T. Rowe Price Investment Management, Inc. has disclosed a 5.7% beneficial ownership stake in ERASCA INC, holding over 16 million shares of common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 5.3% beneficial ownership stake in Erasca, Inc.'s common stock as of January 7, 2026.

Logos Global Management LP and its affiliates have reduced their beneficial ownership in Erasca, Inc. to 4.8% of the common stock.

Logos Global Management LP, along with its general partner and control person, reported a 5.3% passive beneficial ownership stake in Erasca, Inc. common stock.